Compagnie Lombard Odier SCmA Has $8.58 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Compagnie Lombard Odier SCmA decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 7.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 128,304 shares of the company's stock after selling 9,982 shares during the period. Compagnie Lombard Odier SCmA's holdings in Moderna were worth $8,575,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Cedar Wealth Management LLC grew its holdings in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock valued at $31,000 after buying an additional 90 shares during the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company's stock valued at $660,000 after buying an additional 93 shares during the last quarter. CVA Family Office LLC grew its holdings in Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company's stock valued at $64,000 after buying an additional 96 shares during the last quarter. Claro Advisors LLC grew its holdings in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company's stock worth $659,000 after purchasing an additional 108 shares in the last quarter. Finally, McAdam LLC grew its holdings in shares of Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company's stock worth $1,315,000 after purchasing an additional 117 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the business's stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the company's stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $122.84, for a total value of $1,842,600.00. Following the completion of the sale, the director now owns 2,254,015 shares in the company, valued at approximately $276,883,202.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 715 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,184 shares of company stock worth $7,464,331 over the last 90 days. 15.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent research reports. Barclays decreased their price objective on Moderna from $155.00 to $125.00 and set an "overweight" rating on the stock in a report on Monday, September 16th. Deutsche Bank Aktiengesellschaft raised Moderna from a "sell" rating to a "hold" rating and decreased their price objective for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Evercore ISI reissued an "in-line" rating and set a $120.00 price objective on shares of Moderna in a report on Thursday, June 27th. Hsbc Global Res raised Moderna from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 28th. Finally, TD Cowen decreased their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating on the stock in a report on Friday, September 13th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $100.44.

Moderna Price Performance

MRNA traded up $1.46 during trading on Friday, hitting $58.29. The company's stock had a trading volume of 6,260,992 shares, compared to its average volume of 4,342,003. The firm's 50 day moving average price is $73.45 and its two-hundred day moving average price is $106.33. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12 month low of $55.70 and a 12 month high of $170.47. The stock has a market capitalization of $22.34 billion, a price-to-earnings ratio of -3.72 and a beta of 1.66.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business's revenue for the quarter was down 29.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($3.62) EPS. Sell-side analysts forecast that Moderna, Inc. will post -9.85 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.